A
ENTA icon

AlphaQuest’s Enanta Pharmaceuticals ENTA Stock Holding History

AlphaQuest’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,178
Closed -$224K – 651
2025
Q4 		$224K Buy
14,178
+3,980
+39% +$50.5K 0.01% 1388
2025
Q3 		$122K Buy
10,198
+1,562
+18% +$12.5K 0.01% 1640
2025
Q2 		$65.3K Hold
8,636
– – 0.01% 1558
2025
Q1 		$47.7K Sell
8,636
-13,624
-61% -$84.2K 0.01% 1542
2024
Q4 		$128K Buy
22,260
+3,137
+16% +$30.1K 0.02% 1029
2024
Q3 		$198K Buy
19,123
+7,535
+65% +$98.5K 0.02% 1077
2024
Q2 		$150K Buy
11,588
+9,692
+511% +$131K 0.02% 836
2024
Q1 		$33.1K Sell
1,896
-13,569
-88% -$180K 0.01% 978
2023
Q4 		$146K Buy
+15,465
New +$144K 0.03% 697

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AlphaQuest's ENTA Position: Q1 2026 in Review

AlphaQuest sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 14,178 shares — an estimated $224K sold.

AlphaQuest first reported a position in ENTA in Q4 2023 and held it in 9 quarters. The position peaked at $224K in Q4 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • AlphaQuest reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 14,178 Enanta Pharmaceuticals shares in Q1 2026, an estimated $224K.
  • AlphaQuest first reported a position in Enanta Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • AlphaQuest's Enanta Pharmaceuticals position peaked at $224K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.